More info
Novel PCSK9-LDLR disruptor, reducing plasma cholesterol levels and increases hepatic LDLR density in a dose-dependent manner, functioning by a unique, allosteric mechanism and being the smallest molecule identified to date with in vivo PCSK9-LDLR disruptor function